Myeloablative haploidentical hematopoietic stem cell transplantation using basiliximab for graft-versus-host disease prophylaxis
Myeloablative haploidentical hematopoietic stem cell transplantation using basiliximab for graft-versus-host disease prophylaxis
复制标题
使用巴利昔单抗进行清髓性单倍相合造血干细胞移植预防移植物抗宿主病
DOI：
10.1179/1607845414y.0000000207
复制
发表时间：
2015-07
期刊：
影响因子：
1.9
通讯作者：
Li Yuhua
中科院分区：
文献类型：
--
作者：
Huang Rui;Tu Sanfang;Deng Lan;Kang Qian;Song Chaoyang;Li Yuhua
摘要目的回顾性比较巴利昔单抗与抗胸腺细胞球蛋白(ATG)对白血病患者半相合造血干细胞移植(HSCT)后的预防作用。方法回顾分析巴利昔单抗预防移植物抗宿主病(GVHD)10例和ATG预防GVHD 24例的半相合HSCT。结果所有患者均获得中性粒细胞植入。ATG组有1例患者未植入血小板。巴利昔单抗组II-IV级和III-IV级急性移植物抗宿主病的发生率分别为30%和20%，ATG组分别为16.7%和4.2%(P&gT；0.05)。巴利昔单抗组和ATG组分别有40%和22.2%的患者发生广泛的cGVHD(P>；0.05)。巴利昔单抗感染轻微，感染相关死亡率低(10%)；ATG感染较重，感染相关死亡率29.2%(P>；0.05)。在随访期内，巴利昔单抗组和ATG组分别有20%和22.7%的患者复发(P>；0.05)。巴利昔单抗组和ATG组的3年累积总生存率分别为80%和52.5%，3年无白血病生存率分别为60%和49.6%(P>；0.05)。[讨论]巴利昔单抗组II-IV级和III-IV级aGVHD的发生率与含ATG的半相合HSCT组相似。与ATG组相比，巴利昔单抗组移植相关死亡率较低，长期存活率较好，但无统计学意义。结论巴利昔单抗联合半相合HSCT预防GVHD是安全可行的。需要更多的研究来证实这一点。
Abstract Objectives We retrospectively compared the prophylactic effect of basiliximab and antithymocyte globulin (ATG) after haploidentical hematopoietic stem cell transplantation (HSCT) in patients with leukemia. Methods Haploidentical HSCT using basiliximab for graft-versus-host disease (GVHD) prophylaxis in 10 patients with leukemia was retrospectively compared to ATG for GVHD prophylaxis in 24 patients. Results All the patients achieved neutrophil engraftment. One patient in the ATG group did not achieve platelet engraftment. The incidence of grade II–IV and grade III–IV acute GVHD was 30 and 20%, respectively, in the basiliximab group and 16.7 and 4.2%, respectively, in the ATG group (P > 0.05). Extensive cGVHD developed in 40 and 22.2% of patients in the basiliximab group and ATG group, respectively (P > 0.05). Basiliximab resulted in mild infection and a low incidence (10%) of infection-related mortality; ATG resulted in relative severe infection with 29.2% infection-related mortality (P > 0.05). During the follow-up period, 20% of the basiliximab group and 22.7% of the ATG group relapsed (P > 0.05). In the basiliximab group and the ATG group, the 3-year accumulative overall survival rate was, respectively, 80 and 52.5% and the 3-year leukemia-free survival, respectively, was 60 and 49.6% (P > 0.05). Discussion The incidences of grade II–IV and grade III–IV aGVHD in the basiliximab group were similar to those in halpoidentical HSCT containing ATG. Compared to the ATG group, the basiliximab group had a lower rate of transplantation-related mortality and better long-term survival, but without statistical significance. Conclusion The prophylactic regimen of basiliximab with haploidentical HSCT against GVHD seems safe and promising. More studies needed to verify this.
登录
查看更多内容
使用巴利昔单抗进行清髓性单倍相合造血干细胞移植预防移植物抗宿主病
影响因子：
1.9
作者：
Huang Rui;Tu Sanfang;Deng Lan;Kang Qian;Song Chaoyang;Li Yuhua
通讯作者：
Li Yuhua
影响因子：
28.5
作者：
Lv M;Huang XJ
通讯作者：
Huang XJ
使用未操作的 HLA 不匹配/半相合血液和骨髓移植治疗急性白血病。
影响因子：
4.3
作者：
Huang, Xiao-Jun;Liu, Dai-Hong;Lu, Dao-Pei
通讯作者：
Lu, Dao-Pei
DOI：
10.1016/j.critrevonc.2013.03.009
发表时间：
2013-10
期刊：
Critical reviews in oncology/hematology
影响因子：
--
作者：
S. Theurich;Hans Fischmann;G. Chakupurakal;A. Shimabukuro-Vornhagen;J. Chemnitz;U. Holtick;A. Rothe;C. Scheid;M. Hallek;N. Skoetz;M. von Bergwelt-Baildon
通讯作者：
S. Theurich;Hans Fischmann;G. Chakupurakal;A. Shimabukuro-Vornhagen;J. Chemnitz;U. Holtick;A. Rothe;C. Scheid;M. Hallek;N. Skoetz;M. von Bergwelt-Baildon
影响因子：
3.6
作者：
Guiqing Yao;E. Albon;Yaser Adi;D. Milford;Susan Bayliss;A. Ready;James Raftery;Rodney Taylor
通讯作者：
Guiqing Yao;E. Albon;Yaser Adi;D. Milford;Susan Bayliss;A. Ready;James Raftery;Rodney Taylor